Clinical Trial Update: Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003) [Phase 2]

View source ↗

Summary

Phase 2 long-term extension trial update for rAvPAL-PEG in phenylketonuria (PKU) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• rAvPAL-PEG (recombinant phenylalanine ammonia-lyase enzyme PEGylated)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria | Phase 2 | Status: COMPLETED | Results posted: 2021-10-12